DK0706398T3 - Farmaceutisk sammensætning indeholdende heparin, heparinfragmenter eller derivater heraf i kombination med glycerolestere - Google Patents

Farmaceutisk sammensætning indeholdende heparin, heparinfragmenter eller derivater heraf i kombination med glycerolestere

Info

Publication number: DK0706398T3
Authority: DK; Denmark
Prior art keywords: heparin; pct; derivatives; combination; glycerol esters
Prior art date: 1993-06-18

Application number

DK94919936T

Other languages

Danish (da)

English (en)

Inventor

Monica Einarsson

Original Assignee

Pharmacia Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-06-18

Filing date

1994-06-16

Publication date

2002-05-21

1994-06-16 Application filed by Pharmacia Ab filed Critical Pharmacia Ab

2002-05-21 Application granted granted Critical

2002-05-21 Publication of DK0706398T3 publication Critical patent/DK0706398T3/da

Links

HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title abstract 2
150000002314 glycerols Chemical class 0.000 title abstract 2
229960002897 heparin Drugs 0.000 title abstract 2
229920000669 heparin Polymers 0.000 title abstract 2
239000002634 heparin fragment Substances 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
239000002628 heparin derivative Substances 0.000 title 1
239000000203 mixture Substances 0.000 abstract 3
238000010521 absorption reaction Methods 0.000 abstract 2
239000003623 enhancer Substances 0.000 abstract 2
230000006978 adaptation Effects 0.000 abstract 1
239000000654 additive Substances 0.000 abstract 1
239000000969 carrier Substances 0.000 abstract 1
235000014113 dietary fatty acids Nutrition 0.000 abstract 1
239000003085 diluting agent Substances 0.000 abstract 1
229930195729 fatty acid Natural products 0.000 abstract 1
239000000194 fatty acid Substances 0.000 abstract 1
150000004665 fatty acids Chemical class 0.000 abstract 1
210000004400 mucous membrane Anatomy 0.000 abstract 1
238000007920 subcutaneous administration Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

DK94919936T 1993-06-18 1994-06-16 Farmaceutisk sammensætning indeholdende heparin, heparinfragmenter eller derivater heraf i kombination med glycerolestere DK0706398T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE19939302135A SE9302135D0 (sv)	1993-06-18	1993-06-18	New pharmaceutical composition
PCT/SE1994/000595 WO1995000152A1 (en)	1993-06-18	1994-06-16	Pharmaceutical composition containing heparin, heparin fragments or their derivatives in combination with glycerol esters

Publications (1)

Publication Number	Publication Date
DK0706398T3 true DK0706398T3 (da)	2002-05-21

Family

ID=20390356

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK94919936T DK0706398T3 (da)	1993-06-18	1994-06-16	Farmaceutisk sammensætning indeholdende heparin, heparinfragmenter eller derivater heraf i kombination med glycerolestere

Country Status (10)

Country	Link
US (1)	US5714477A (de)
EP (1)	EP0706398B1 (de)
JP (1)	JP3953510B2 (de)
AT (1)	ATE209038T1 (de)
DE (1)	DE69429169T2 (de)
DK (1)	DK0706398T3 (de)
ES (1)	ES2168299T3 (de)
PT (1)	PT706398E (de)
SE (1)	SE9302135D0 (de)
WO (1)	WO1995000152A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6008228A (en) *	1995-06-06	1999-12-28	Hoffman-La Roche Inc.	Pharmaceutical compositions containing proteinase inhibitors
SE9602145D0 (sv) *	1996-05-31	1996-05-31	Astra Ab	New improved formulation for treatment of thromboembolism
US20070148228A1 (en) *	1999-02-22	2007-06-28	Merrion Research I Limited	Solid oral dosage form containing an enhancer
US8119159B2 (en) *	1999-02-22	2012-02-21	Merrion Research Iii Limited	Solid oral dosage form containing an enhancer
US7658938B2 (en) *	1999-02-22	2010-02-09	Merrion Reasearch III Limited	Solid oral dosage form containing an enhancer
US6761903B2 (en)	1999-06-30	2004-07-13	Lipocine, Inc.	Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6248363B1 (en) *	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6982281B1 (en) *	2000-11-17	2006-01-03	Lipocine Inc	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US20030236236A1 (en) *	1999-06-30	2003-12-25	Feng-Jing Chen	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6458383B2 (en)	1999-08-17	2002-10-01	Lipocine, Inc.	Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
CA2377734A1 (en) *	1999-06-30	2001-01-11	Hamilton Civic Hospitals Research Development, Inc.	Heparin compositions that inhibit clot associated coagulation factors
EP1251867A4 (de)	2000-02-04	2004-12-08	Unigene Lab Inc	Nasale calcitoninformulierungen
DE10026699A1 (de) *	2000-05-30	2001-12-06	Basf Ag	Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage
CA2420890A1 (en) *	2000-09-08	2002-03-14	Hamilton Civic Hospitals Research Development, Inc.	Antithrombotic compositions
WO2002092070A1 (en) *	2001-05-11	2002-11-21	Elan Corporation, Plc	Isostearic acid salts as permeation enhancers
EP1390383B1 (de) *	2001-05-11	2012-02-29	Isis Pharmaceuticals, Inc.	Antisense-permeationsverstärker
CA2454587C (en) *	2001-07-25	2012-11-13	Protein Design Labs, Inc.	Stable lyophilized pharmaceutical formulation of igg antibodies
SE521676C2 (sv)	2002-01-02	2003-11-25	Dilafor Ab	Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
EP1542704A1 (de) *	2002-04-18	2005-06-22	Stephen H. Embury	VERFAHREN UND ZUSAMMENSETZUNG ZUR PRûVENTION VON SCHMERZEN BEI SICHELZELL-PATIENTEN
US20060003002A1 (en) *	2003-11-03	2006-01-05	Lipocine, Inc.	Pharmaceutical compositions with synchronized solubilizer release
US20070219131A1 (en) *	2004-04-15	2007-09-20	Ben-Sasson Shmuel A	Compositions capable of facilitating penetration across a biological barrier
US8241670B2 (en) *	2004-04-15	2012-08-14	Chiasma Inc.	Compositions capable of facilitating penetration across a biological barrier
WO2005107773A2 (en) *	2004-05-06	2005-11-17	Emisphere Technologies, Inc.	Solid dosage form of wetted heparin
NZ551196A (en)	2004-05-14	2010-08-27	Emisphere Tech Inc	Compounds and compositions for delivering active agents
US20050282775A1 (en) *	2004-06-16	2005-12-22	Paringenix, Inc.	Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
US7563780B1 (en) *	2004-06-18	2009-07-21	Advanced Cardiovascular Systems, Inc.	Heparin prodrugs and drug delivery stents formed therefrom
ZA200801696B (en) *	2005-07-22	2009-08-26	Univ California	Heparin compositions and selection inhibition
US20070154546A1 (en) *	2005-12-30	2007-07-05	Zhang Jack Y	Sustained release pharmaceutical compositions
KR101191322B1 (ko) *	2006-04-07	2012-10-16	메리온 리서치 Ⅲ 리미티드	증진제를 함유하는 고형 경구용 투여 제형
EP2040731A4 (de) *	2006-06-09	2010-05-19	Merrion Res Iii Ltd	Feste orale dosierform mit einem verstärkungsmittel
CN107096012A (zh) *	2008-05-07	2017-08-29	诺和诺德股份有限公司	肽的组合物及其制备方法
CN102176900B (zh)	2008-09-17	2017-09-26	克艾思马有限公司	药物组合物和相关的给药方法
US11304960B2 (en)	2009-01-08	2022-04-19	Chandrashekar Giliyar	Steroidal compositions
US20100215743A1 (en) *	2009-02-25	2010-08-26	Leonard Thomas W	Composition and drug delivery of bisphosphonates
AU2010339907A1 (en)	2009-12-16	2012-07-05	Nod Pharmaceuticals, Inc.	Compositions and methods for oral drug delivery
US20110142889A1 (en) *	2009-12-16	2011-06-16	Nod Pharmaceuticals, Inc.	Compositions and methods for oral drug delivery
BR112012015016B8 (pt)	2009-12-18	2021-05-25	Catalent France Beinheim Sa	formulação farmacêutica, forma de dosagem farmacêutica entérica e uso de uma formulação
US20110182985A1 (en) *	2010-01-28	2011-07-28	Coughlan David C	Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (en) *	2010-03-26	2011-09-29	Merrion Research Iii Limited	Pharmaceutical compositions of selective factor xa inhibitors for oral administration
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20180153904A1 (en)	2010-11-30	2018-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9358241B2 (en)	2010-11-30	2016-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20120148675A1 (en)	2010-12-10	2012-06-14	Basawaraj Chickmath	Testosterone undecanoate compositions
EP2661273A4 (de)	2011-01-07	2014-06-04	Merrion Res Iii Ltd	Pharmazeutische zusammensetzungen aus eisen zur oralen verabreichung
CN108498532B (zh)	2012-05-09	2021-07-23	坎泰克斯制药股份有限公司	骨髓抑制的治疗
US9498485B2 (en)	2014-08-28	2016-11-22	Lipocine Inc.	Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US10265384B2 (en)	2015-01-29	2019-04-23	Novo Nordisk A/S	Tablets comprising GLP-1 agonist and enteric coating
HUE071943T2 (hu)	2015-02-03	2025-10-28	Amryt Endo Inc	Akromegália kezelése oktreotid orális alkalmazásával
US10052346B2 (en)	2015-02-17	2018-08-21	Cantex Pharmaceuticals, Inc.	Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
US20160361322A1 (en)	2015-06-15	2016-12-15	Lipocine Inc.	Composition and method for oral delivery of androgen prodrugs
US11559530B2 (en)	2016-11-28	2023-01-24	Lipocine Inc.	Oral testosterone undecanoate therapy
AU2019308326B2 (en)	2018-07-20	2025-07-31	Lipocine Inc.	Liver disease
EP3870155A4 (de) *	2018-10-25	2023-08-09	Zeenar Enterprises Pty Ltd	Zusammensetzung zur formung von flüssigkristallinen partikeln
US11141457B1 (en)	2020-12-28	2021-10-12	Amryt Endo, Inc.	Oral octreotide therapy and contraceptive methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3510561A (en) *	1965-05-20	1970-05-05	Canada Packers Ltd	Sulfone-enhanced heparin absorption through mucous membranes
JPS53107408A (en) *	1977-02-28	1978-09-19	Yamanouchi Pharmaceut Co Ltd	Micellar preparation for rectal infusion
CA1136620A (en) *	1979-01-08	1982-11-30	Ulf P.F. Lindahl	Heparin fragments having selective anticoagulation activity
DE3171774D1 (en) *	1980-03-31	1985-09-19	Teijin Ltd	Pharmaceutical composition for intrarectal administration, and suppository prepared therefrom
JPS6028972A (ja) *	1983-06-29	1985-02-14	Kyowa Hakko Kogyo Co Ltd	ジベンゾ［ｂ，ｅ］オキセピン誘導体
DE3331009A1 (de) *	1983-08-27	1985-03-14	Basf Ag, 6700 Ludwigshafen	Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
FR2616661B1 (fr) *	1987-06-19	1991-06-07	Doutremepuich Christian	Composition a base de mucopolysaccharides hepariniques, active par voie orale
DE3805523A1 (de) *	1988-02-22	1989-10-05	Schur Pharmazeutika Gmbh & Co	Pharmazeutische praeparate zur transdermalen applikation von heparin

1993
- 1993-06-18 SE SE19939302135A patent/SE9302135D0/xx unknown
1994
- 1994-06-16 ES ES94919936T patent/ES2168299T3/es not_active Expired - Lifetime
- 1994-06-16 JP JP50271195A patent/JP3953510B2/ja not_active Expired - Fee Related
- 1994-06-16 PT PT94919936T patent/PT706398E/pt unknown
- 1994-06-16 EP EP94919936A patent/EP0706398B1/de not_active Expired - Lifetime
- 1994-06-16 DE DE69429169T patent/DE69429169T2/de not_active Expired - Fee Related
- 1994-06-16 AT AT94919936T patent/ATE209038T1/de not_active IP Right Cessation
- 1994-06-16 US US08/569,087 patent/US5714477A/en not_active Expired - Fee Related
- 1994-06-16 WO PCT/SE1994/000595 patent/WO1995000152A1/en not_active Ceased
- 1994-06-16 DK DK94919936T patent/DK0706398T3/da active

Also Published As

Publication number	Publication date
JP3953510B2 (ja)	2007-08-08
SE9302135D0 (sv)	1993-06-18
US5714477A (en)	1998-02-03
DE69429169D1 (de)	2002-01-03
EP0706398A1 (de)	1996-04-17
ES2168299T3 (es)	2002-06-16
EP0706398B1 (de)	2001-11-21
WO1995000152A1 (en)	1995-01-05
DE69429169T2 (de)	2002-06-20
ATE209038T1 (de)	2001-12-15
JPH09501652A (ja)	1997-02-18
PT706398E (pt)	2002-05-31

Publication	Publication Date	Title
DK0706398T3 (da)	2002-05-21	Farmaceutisk sammensætning indeholdende heparin, heparinfragmenter eller derivater heraf i kombination med glycerolestere
EP1153924A3 (de)	2001-11-21	Substutuierte 1,3-Oxathiolane mit antiviralen Eigenschaften
FI963398A0 (fi)	1996-08-30	Kielenalainen tai poskensisäinen farmaseuttinen koostumus
TR200001982T2 (tr)	2001-02-21	Farmasötik vurulu salınımlı oral dozaj şekli.
BR9810450A (pt)	2000-09-05	Derivados de ácido barbitúrico com atividade antimetastática e antitumor
AU4884696A (en)	1996-09-18	Pharmaceutical compositions comprising monoamine oxidase B inhibitors
DE69713300D1 (de)	2002-07-18	Benzopyran derivate mit leukotrien-antagonistischer wirkung
ATE148990T1 (de)	1997-03-15	Ebastin oder ebastin-analoga enthaltende arzneimittel
ATE165827T1 (de)	1998-05-15	Herstellung von n-acetylneuraminsäure-derivaten
TR200000153T2 (tr)	2000-07-21	İl-5 inhibite eden 6-azaurasil türevleri.
DK0937060T3 (da)	2003-04-07	Nye cis-3,4-chroman-derivater, der er nyttige i forebyggelsen eller behandlingen af østrogen-relaterede sygdomme eller syndromer
FR2756826B1 (fr)	1999-01-08	Nouveaux derives tetrahydropyridiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ATE59295T1 (de)	1991-01-15	Prazosin-pirbuterol-mischung zur bronchendilatation.
FI951277A0 (fi)	1995-03-17	Uudet N,N,N',N'-tetrasubstituoituneet 1,2-etaanidiamiinijohdannaisyhdisteet
DK0937057T3 (da)	2003-05-05	Hidtil ukendte (-)-enantiomerer af cis-3,4-chromanderivater anvendelige i forebyggelse eller behandling af østrogenrelaterede sygdomme eller syndromer
DK0937062T3 (da)	2003-04-07	Nye cis-3,4-chroman-derivater, der er nyttige i forebyggelsen eller behandlingen af østrogen-relaterede sygdomme eller syndromer
CA2434775A1 (en)	2002-07-25	Compounds for use in the treatment of skin conditions
DE69931504D1 (de)	2006-06-29	Zusammensetzungen zur linderung der nebeneffekte des interleukin-2
SE8303031D0 (sv)	1983-05-30	Improved steroid esters preparation
ATE145197T1 (de)	1996-11-15	Lagerstabile lösungen von carbonisiertem magnesiumethylat in ethanol sowie deren herstellung und verwendung
SE1214315T3 (de)	2003-08-12
ES2145541T3 (es)	2000-07-01	Nuevos seco-d-esteroides activos sobre el sistema cardiovascular, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.